trending Market Intelligence /marketintelligence/en/news-insights/trending/C-Y5AVqP00jVqab1gWptXg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Belgium's UCB to build €300M manufacturing facility, hire 150 employees

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Belgium's UCB to build €300M manufacturing facility, hire 150 employees

UCB SA said it will build a €300-million manufacturing unit in Belgium and hire about 150 employees for it.

The Brussels-based pharmaceutical company said it expects the multi-product biological manufacturing facility to be operational by 2024.

The unit will be constructed at Braine l'Alleud in Wallonia, Belgium, UCB added.

"The shift of our pipeline towards large molecules requires us to ramp up investment in mammalian technical development, as well as our manufacturing capabilities," UCB executive vice president Kirsten Lund-Jurgensen said in a statement.

Earlier this year, UCB entered an agreement to acquire autoimmune disease therapy developer Ra Pharmaceuticals Inc. in a $2.1-billion deal which is expected to close by the end of the first quarter of 2020.